

Limitless Potential.
Precision Design.
Enduring Impact.
Aiming to transform treatment of cancer and autoimmune diseases by developing allogeneic, iPSC-derived NK and T cell therapies.
PRESS RELEASES + EVENTS
view all
May 15, 2025
Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to…
April 28, 2025
Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting
PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) — Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative…



About us
We are building an industry leading allogeneic iPSC-derived cell therapy platform for cancer and autoimmune diseases.






OUR SCIENCE
We are leveraging the unlimited self-renewing capacity of induced pluripotent stem cells (iPSC) and cutting-edge cellular engineering and manufacturing technologies to develop fit-for-purpose products with functionalities designed to overcome the limitations of existing cell therapies.
